{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:19:04Z","timestamp":1790515144086,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["19K18586"],"award-info":[{"award-number":["19K18586"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Vicky Joseph Cancer Research Foundation"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA209859"],"award-info":[{"award-number":["R35 CA209859"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ONECUT2 is a lineage plasticity driver and therapeutic target in aggressive prostate cancer (PCa). This study investigated whether ONECUT2 gene-body DNA methylation regulates its expression and assessed its potential as a biomarker in clinical specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed associations between ONECUT2 gene-body methylation, expression, and patient survival across multiple datasets. The effect of DNA methylation on ONECUT2 expression was tested in prostate cancer cell lines using a DNA methyltransferase inhibitor (DNMTi). Validation was further performed in needle biopsy samples by targeted bisulfite sequencing for DNA methylation and RT-PCR for gene expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ONECUT2 expression strongly correlated with gene-body DNA methylation and patient survival in multiple datasets. DNMTi treatment confirmed this relationship in prostate cancer cells. In 208 biopsies from prostate cancer patients, hypermethylation of gene-body of ONECUT2 was linked to higher ONECUT2 expression and effectively distinguished tumor from adjacent normal tissue (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 and AUC\u2009=\u20090.86). It also predicted aggressive features, including higher Gleason score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01 and AUC\u2009=\u20090.68), advanced T stage (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04 and AUC\u2009=\u20090.65), seminal vesicle invasion (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0024 and AUC\u2009=\u20090.76), and lymph node involvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005 and AUC\u2009=\u20090.80).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Assessing ONECUT2 gene-body methylation in biopsies may serve as a surrogate for ONECUT2 expression and provide predictive insights into disease progression before surgery. Furthermore, suppressing ONECUT2 through DNMTi treatment represents a potential therapeutic strategy for aggressive PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-026-00890-7","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:03:27Z","timestamp":1768579407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene-body DNA methylation of ONECUT2 predicts its expression and prostate cancer aggressiveness in needle biopsies"],"prefix":"10.1186","volume":"14","author":[{"given":"Yohei","family":"Sekino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo Storino","family":"Ramacciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Mingxue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingda","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Aron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Yong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Luis","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangning","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"3","key":"890_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"890_CR2","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, Bray F, Brawley O, Luckenbaugh AN, Mucci L et al : 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol 2023.","DOI":"10.1016\/j.eururo.2023.04.021"},{"issue":"6","key":"890_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","volume":"80","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N\u2019Dow J, S\u00f8nksen J, Stenzl A, Wirth M. Prostate-specific antigen testing as part of a Risk-Adapted early detection strategy for prostate cancer: European association of urology position and recommendations for 2021. Eur Urol. 2021;80(6):703\u201311.","journal-title":"Eur Urol"},{"issue":"12","key":"890_CR4","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","volume":"24","author":"M Rotinen","year":"2018","unstructured":"Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yanez A, Hazelett DJ, et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat Med. 2018;24(12):1887\u201398.","journal-title":"Nat Med"},{"issue":"13","key":"890_CR5","doi-asserted-by":"publisher","first-page":"7740","DOI":"10.1093\/nar\/gkae547","volume":"52","author":"C Qian","year":"2024","unstructured":"Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, et al. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024;52(13):7740\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"890_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eururo.2004.09.007","volume":"47","author":"N Vashchenko","year":"2005","unstructured":"Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol. 2005;47(2):147\u201355.","journal-title":"Eur Urol"},{"issue":"1","key":"890_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","volume":"10","author":"H Guo","year":"2019","unstructured":"Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun. 2019;10(1):278.","journal-title":"Nat Commun"},{"key":"890_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-43624-1_7","volume":"945","author":"R Lakshminarasimhan","year":"2016","unstructured":"Lakshminarasimhan R, Liang G. The role of DNA methylation in cancer. Adv Exp Med Biol. 2016;945:151\u201372.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"890_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/15592294.2017.1311434","volume":"12","author":"G Liang","year":"2017","unstructured":"Liang G, Weisenberger DJ. DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics. 2017;12(6):416\u201332.","journal-title":"Epigenetics"},{"issue":"4","key":"890_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","volume":"25","author":"S Saghafinia","year":"2018","unstructured":"Saghafinia S, Mina M, Riggi N, Hanahan D, Ciriello G. Pan-Cancer landscape of aberrant DNA methylation across human tumors. Cell Rep. 2018;25(4):1066\u2013e10801068.","journal-title":"Cell Rep"},{"issue":"10149","key":"890_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(18)31268-6","volume":"392","author":"Y Dor","year":"2018","unstructured":"Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777\u201386.","journal-title":"Lancet"},{"issue":"7","key":"890_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484\u201392.","journal-title":"Nat Rev Genet"},{"issue":"4","key":"890_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2014.07.028","volume":"26","author":"X Yang","year":"2014","unstructured":"Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 2014;26(4):577\u201390.","journal-title":"Cancer Cell"},{"issue":"1","key":"890_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13148-022-01382-9","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang B, Chen Y. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin Epigenetics. 2022;14(1):154.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"890_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13059-016-1129-3","volume":"18","author":"K Mundbjerg","year":"2017","unstructured":"Mundbjerg K, Chopra S, Alemozaffar M, Duymich C, Lakshminarasimhan R, Nichols PW, Aron M, Siegmund KD, Ukimura O, Aron M, et al. Identifying aggressive prostate cancer foci using a DNA methylation classifier. Genome Biol. 2017;18(1):3.","journal-title":"Genome Biol"},{"issue":"6","key":"890_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"890_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","volume":"8","author":"S Varambally","year":"2005","unstructured":"Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8(5):393\u2013406.","journal-title":"Cancer Cell"},{"issue":"14","key":"890_CR18","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.2004.05.158","volume":"22","author":"YP Yu","year":"2004","unstructured":"Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004;22(14):2790\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"890_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11\u201322.","journal-title":"Cancer Cell"},{"issue":"3","key":"890_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI66666","volume":"123","author":"C Cai","year":"2013","unstructured":"Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013;123(3):1109\u201322.","journal-title":"J Clin Invest"},{"issue":"3","key":"890_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012;18(3):666\u201377.","journal-title":"Clin Cancer Res"},{"issue":"7406","key":"890_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343.","journal-title":"Nature"},{"issue":"20","key":"890_CR23","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","volume":"21","author":"X Zhang","year":"2015","unstructured":"Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, Lam HM, Dumpit R, Corey E, Chery L, et al. SRRM4 expression and the loss of REST activity May promote the emergence of the neuroendocrine phenotype in Castration-Resistant prostate cancer. Clin Cancer Res. 2015;21(20):4698\u2013708.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"890_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ebiom.2015.07.017","volume":"2","author":"H Ross-Adams","year":"2015","unstructured":"Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2015;2(9):1133\u201344.","journal-title":"EBioMedicine"},{"issue":"4","key":"890_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22(4):369\u201378.","journal-title":"Nat Med"},{"issue":"6","key":"890_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.euf.2017.01.016","volume":"4","author":"BA Luca","year":"2018","unstructured":"Luca BA, Brewer DS, Edwards DR, Edwards S, Whitaker HC, Merson S, Dennis N, Cooper RA, Hazell S, Warren AY, et al. DESNT: A poor prognosis category of human prostate cancer. Eur Urol Focus. 2018;4(6):842\u201350.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"890_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1186\/s12885-017-3729-z","volume":"17","author":"HK Tsai","year":"2017","unstructured":"Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017;17(1):759.","journal-title":"BMC Cancer"},{"issue":"10","key":"890_CR28","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, Nguyen HM, Yang YC, da Costa RMG, Kaipainen A, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129(10):4492\u2013505.","journal-title":"J Clin Invest"},{"issue":"3","key":"890_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305.","journal-title":"Nat Med"},{"issue":"8","key":"890_CR30","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/annonc\/mdy224","volume":"29","author":"A Kamoun","year":"2018","unstructured":"Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, Irani J, Leroy X, Villers A, Fournier G, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;29(8):1814\u201321.","journal-title":"Ann Oncol"},{"issue":"7637","key":"890_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","volume":"541","author":"M Fraser","year":"2017","unstructured":"Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541(7637):359\u201364.","journal-title":"Nature"},{"issue":"1","key":"890_CR32","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1038\/s41467-021-27223-6","volume":"12","author":"J Livingstone","year":"2021","unstructured":"Livingstone J, Shiah YJ, Yamaguchi TN, Heisler LE, Huang V, Lesurf R, Gebo T, Carlin B, Eng S, Drysdale E, et al. The telomere length landscape of prostate cancer. Nat Commun. 2021;12(1):6893.","journal-title":"Nat Commun"},{"issue":"1","key":"890_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13148-019-0736-8","volume":"11","author":"R Toth","year":"2019","unstructured":"Toth R, Schiffmann H, Hube-Magg C, B\u00fcscheck F, H\u00f6flmayer D, Weidemann S, Lebok P, Fraune C, Minner S, Schlomm T, et al. Random forest-based modelling to detect biomarkers for prostate cancer progression. Clin Epigenetics. 2019;11(1):148.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"890_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13148-021-01155-w","volume":"13","author":"R Silva","year":"2021","unstructured":"Silva R, Moran B, Baird AM, O\u2019Rourke CJ, Finn SP, McDermott R, Watson W, Gallagher WM, Brennan DJ, Perry AS. Longitudinal analysis of individual CfDNA methylome patterns in metastatic prostate cancer. Clin Epigenetics. 2021;13(1):168.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"890_CR35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13148-021-01119-0","volume":"13","author":"EB Ylitalo","year":"2021","unstructured":"Ylitalo EB, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S, Widmark A, Hultdin M, Bergh A, Degerman S, et al. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin Epigenetics. 2021;13(1):133.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"890_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1158\/2767-9764.CRC-23-0248","volume":"4","author":"O Dairo","year":"2024","unstructured":"Dairo O, DePaula Oliveira L, Schaffer E, Vidotto T, Mendes AA, Lu J, Huynh SV, Hicks J, Sowalsky AG, De Marzo AM, et al. FASN gene methylation is associated with fatty acid synthase expression and Clinical-genomic features of prostate cancer. Cancer Res Commun. 2024;4(1):152\u201363.","journal-title":"Cancer Res Commun"},{"key":"890_CR37","doi-asserted-by":"crossref","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G, McKenney JK, Melamed J, Mottet N, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol 2020, 44(8):e87\u2013e99.","DOI":"10.1097\/PAS.0000000000001497"},{"issue":"12","key":"890_CR38","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1093\/nar\/25.12.2532","volume":"25","author":"Z Xiong","year":"1997","unstructured":"Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25(12):2532\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"890_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/path.4047","volume":"227","author":"AV Lapuk","year":"2012","unstructured":"Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012;227(3):286\u201397.","journal-title":"J Pathol"},{"issue":"6","key":"890_CR40","first-page":"397","volume":"10","author":"C Qian","year":"2022","unstructured":"Qian C, Yang Q, Freedland SJ, Di Vizio D, Ellis L, You S, Freeman MR. Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer. Am J Clin Exp Urol. 2022;10(6):397\u2013407.","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"890_CR41","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc3130","volume":"11","author":"SB Baylin","year":"2011","unstructured":"Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"14","key":"890_CR42","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1158\/1078-0432.CCR-18-0101","volume":"24","author":"J Gordevicius","year":"2018","unstructured":"Gordevicius J, Krisciunas A, Groot DE, Yip SM, Susic M, Kwan A, Kustra R, Joshua AM, Chi KN, Petronis A, et al. Cell-Free DNA modification dynamics in abiraterone Acetate-Treated prostate cancer patients. Clin Cancer Res. 2018;24(14):3317\u201324.","journal-title":"Clin Cancer Res"},{"issue":"7643","key":"890_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nature21373","volume":"543","author":"F Neri","year":"2017","unstructured":"Neri F, Rapelli S, Krepelova A, Incarnato D, Parlato C, Basile G, Maldotti M, Anselmi F, Oliviero S. Intragenic DNA methylation prevents spurious transcription initiation. Nature. 2017;543(7643):72\u20137.","journal-title":"Nature"},{"issue":"7371","key":"890_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature10442","volume":"479","author":"S Shukla","year":"2011","unstructured":"Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, Oberdoerffer P, Sandberg R, Oberdoerffer S. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature. 2011;479(7371):74\u20139.","journal-title":"Nature"},{"issue":"11","key":"890_CR45","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/nsmb840","volume":"11","author":"MC Lorincz","year":"2004","unstructured":"Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nat Struct Mol Biol. 2004;11(11):1068\u201375.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"890_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015;162(5):961\u201373.","journal-title":"Cell"},{"issue":"1","key":"890_CR47","doi-asserted-by":"publisher","first-page":"112016","DOI":"10.1016\/j.celrep.2023.112016","volume":"42","author":"HT Li","year":"2023","unstructured":"Li HT, Jang HJ, Rohena-Rivera K, Liu M, Gujar H, Kulchycki J, Zhao S, Billet S, Zhou X, Weisenberger DJ, et al. RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer. Cell Rep. 2023;42(1):112016.","journal-title":"Cell Rep"},{"issue":"5","key":"890_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA methylation causes an interferon response in cancer via DsRNA including endogenous retroviruses. Cell. 2015;162(5):974\u201386.","journal-title":"Cell"},{"issue":"7836","key":"890_CR49","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41586-020-2844-1","volume":"588","author":"P Mehdipour","year":"2020","unstructured":"Mehdipour P, Marhon SA, Ettayebi I, Chakravarthy A, Hosseini A, Wang Y, de Castro FA, Loo Yau H, Ishak C, Abelson S, et al. Epigenetic therapy induces transcription of inverted sines and ADAR1 dependency. Nature. 2020;588(7836):169\u201373.","journal-title":"Nature"},{"issue":"2","key":"890_CR50","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cell.2020.11.042","volume":"184","author":"JZ Shen","year":"2021","unstructured":"Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, et al. FBXO44 promotes DNA replication-coupled repetitive element Silencing in cancer cells. Cell. 2021;184(2):352\u201369. e323.","journal-title":"Cell"},{"issue":"1","key":"890_CR51","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1038\/s41467-020-19170-5","volume":"11","author":"H Tunbak","year":"2020","unstructured":"Tunbak H, Enriquez-Gasca R, Tie CHC, Gould PA, Mlcochova P, Gupta RK, Fernandes L, Holt J, van der Veen AG, Giampazolias E, et al. The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s. Nat Commun. 2020;11(1):5387.","journal-title":"Nat Commun"},{"issue":"1","key":"890_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2009","unstructured":"Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27\u201336.","journal-title":"Carcinogenesis"},{"issue":"7","key":"890_CR53","doi-asserted-by":"publisher","first-page":"12484","DOI":"10.18632\/oncotarget.14226","volume":"8","author":"I Faleiro","year":"2017","unstructured":"Faleiro I, Le\u00e3o R, Binnie A, de Mello RA, Maia AT, Castelo-Branco P. Epigenetic therapy in urologic cancers: an update on clinical trials. Oncotarget. 2017;8(7):12484\u2013500.","journal-title":"Oncotarget"},{"key":"890_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fphar.2018.00366","volume":"9","author":"\u00c2 Marques-Magalh\u00e3es","year":"2018","unstructured":"Marques-Magalh\u00e3es \u00c2, Gra\u00e7a I, Henrique R, Jer\u00f3nimo C. Targeting DNA methyltranferases in urological tumors. Front Pharmacol. 2018;9:366.","journal-title":"Front Pharmacol"},{"issue":"3","key":"890_CR55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","volume":"21","author":"HC Tsai","year":"2012","unstructured":"Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21(3):430\u201346.","journal-title":"Cancer Cell"},{"issue":"5","key":"890_CR56","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrclinonc.2013.42","volume":"10","author":"N Azad","year":"2013","unstructured":"Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours\u2013lessons from the past. Nat Rev Clin Oncol. 2013;10(5):256\u201366.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"890_CR57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","volume":"21","author":"E Farah","year":"2022","unstructured":"Farah E, Zhang Z, Utturkar SM, Liu J, Ratliff TL, Liu X. Targeting DNMTs to overcome enzalutamide resistance in prostate cancer. Mol Cancer Ther. 2022;21(1):193\u2013205.","journal-title":"Mol Cancer Ther"},{"key":"890_CR58","doi-asserted-by":"crossref","unstructured":"Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S et al. ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. bioRxiv 2023.","DOI":"10.1101\/2023.09.28.560025"},{"key":"890_CR59","doi-asserted-by":"crossref","unstructured":"Kurdyukov S, Bullock M. DNA methylation analysis: choosing the right method. Biology (Basel) 2016;5(1).","DOI":"10.3390\/biology5010003"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00890-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:45:44Z","timestamp":1781631944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00890-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["890"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00890-7","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institute Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G. Liang is consultant for PANGEA LABORATORY. I.S.G. is a consultant for STEBA. No potential conflicts of interest were disclosed by the other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}